Principles of a new treatment algorithm in multiple sclerosis

Hans-Peter Hartung; Xavier Montalban; Per Soelberg Sorensen; Patrick Vermersch; Tomas Olsson

doi:10.1586/ern.11.15

Principles of a new treatment algorithm in multiple sclerosis

Hans-Peter Hartung, Xavier Montalban, Per Soelberg Sorensen, Patrick Vermersch, Tomas Olsson

Institut for Klinisk Medicin

23 Citationer (Scopus)

Abstract

We are entering a new era in the management of patients with multiple sclerosis (MS). The first oral treatment (fingolimod) has now gained US FDA approval, addressing an unmet need for patients with MS who wish to avoid parenteral administration. A second agent (cladribine) is currently being considered for approval. With the arrival of these oral agents, a key question is where they may fit into the existing MS treatment algorithm. This article aims to help answer this question by analyzing the trial data for the new oral therapies, as well as for existing MS treatments, by applying practical clinical experience, and through consideration of our increased understanding of how to define treatment success in MS. This article also provides a speculative look at what the treatment algorithm may look like in 5 years, with the availability of new data, greater experience and, potentially, other novel agents.

Originalsprog	Engelsk
Tidsskrift	Expert Review of Neurotherapeutics
Vol/bind	11
Udgave nummer	3
Sider (fra-til)	351-62
Antal sider	12
ISSN	1473-7175
DOI	https://doi.org/10.1586/ern.11.15
Status	Udgivet - mar. 2011

Adgang til dokumentet

10.1586/ern.11.15

Citationsformater

@article{f09bac5a4c0a4d2e86fc57b101e1c18c,

title = "Principles of a new treatment algorithm in multiple sclerosis",

abstract = "We are entering a new era in the management of patients with multiple sclerosis (MS). The first oral treatment (fingolimod) has now gained US FDA approval, addressing an unmet need for patients with MS who wish to avoid parenteral administration. A second agent (cladribine) is currently being considered for approval. With the arrival of these oral agents, a key question is where they may fit into the existing MS treatment algorithm. This article aims to help answer this question by analyzing the trial data for the new oral therapies, as well as for existing MS treatments, by applying practical clinical experience, and through consideration of our increased understanding of how to define treatment success in MS. This article also provides a speculative look at what the treatment algorithm may look like in 5 years, with the availability of new data, greater experience and, potentially, other novel agents.",

author = "Hans-Peter Hartung and Xavier Montalban and Sorensen, {Per Soelberg} and Patrick Vermersch and Tomas Olsson",

year = "2011",

month = mar,

doi = "10.1586/ern.11.15",

language = "English",

volume = "11",

pages = "351--62",

journal = "Expert Review of Neurotherapeutics",

issn = "1473-7175",

publisher = "Taylor & Francis",

number = "3",

}

TY - JOUR

T1 - Principles of a new treatment algorithm in multiple sclerosis

AU - Hartung, Hans-Peter

AU - Montalban, Xavier

AU - Sorensen, Per Soelberg

AU - Vermersch, Patrick

AU - Olsson, Tomas

PY - 2011/3

Y1 - 2011/3

N2 - We are entering a new era in the management of patients with multiple sclerosis (MS). The first oral treatment (fingolimod) has now gained US FDA approval, addressing an unmet need for patients with MS who wish to avoid parenteral administration. A second agent (cladribine) is currently being considered for approval. With the arrival of these oral agents, a key question is where they may fit into the existing MS treatment algorithm. This article aims to help answer this question by analyzing the trial data for the new oral therapies, as well as for existing MS treatments, by applying practical clinical experience, and through consideration of our increased understanding of how to define treatment success in MS. This article also provides a speculative look at what the treatment algorithm may look like in 5 years, with the availability of new data, greater experience and, potentially, other novel agents.

AB - We are entering a new era in the management of patients with multiple sclerosis (MS). The first oral treatment (fingolimod) has now gained US FDA approval, addressing an unmet need for patients with MS who wish to avoid parenteral administration. A second agent (cladribine) is currently being considered for approval. With the arrival of these oral agents, a key question is where they may fit into the existing MS treatment algorithm. This article aims to help answer this question by analyzing the trial data for the new oral therapies, as well as for existing MS treatments, by applying practical clinical experience, and through consideration of our increased understanding of how to define treatment success in MS. This article also provides a speculative look at what the treatment algorithm may look like in 5 years, with the availability of new data, greater experience and, potentially, other novel agents.

U2 - 10.1586/ern.11.15

DO - 10.1586/ern.11.15

M3 - Journal article

SN - 1473-7175

VL - 11

SP - 351

EP - 362

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

IS - 3

ER -

Principles of a new treatment algorithm in multiple sclerosis

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater